Isabel J Sible1, Daniel A Nation2,3. 1. Department of Psychology, University of Southern California, Los Angeles, CA, USA. 2. Department of Psychological Science, University of California, Irvine, Irvine, CA, USA. 3. Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Abstract
BACKGROUND: Elevated blood pressure is linked to cognitive impairment and Alzheimer's disease (AD) biomarker abnormality. However, blood pressure levels vary over time. Less is known about the role of long-term blood pressure variability in cognitive impairment and AD pathophysiology. OBJECTIVE: Determine whether long-term blood pressure variability is elevated across the clinical and biomarker spectrum of AD. METHODS: Alzheimer's Disease Neuroimaging Initiative participants (cognitively normal, mild cognitive impairment, AD [n = 1,421]) underwent baseline exam, including blood pressure measurement at 0, 6, and 12 months. A subset (n = 318) underwent baseline lumbar puncture to determine cerebrospinal fluid amyloid-β and phosphorylated tau levels. Clinical groups and biomarker-confirmed AD groups were compared on blood pressure variability over 12 months. RESULTS: Systolic blood pressure variability was elevated in clinically diagnosed AD dementia (VIM: F2,1195 = 6.657, p = 0.001, η2 = 0.01) compared to cognitively normal participants (p = 0.001), and in mild cognitive impairment relative to cognitively normal participants (p = 0.01). Findings were maintained in biomarker-confirmed AD (VIM: F2,850 = 5.216, p = 0.006, η2 = 0.01), such that systolic blood pressure variability was elevated in biomarker-confirmed dementia due to AD relative to cognitively normal participants (p = 0.005) and in biomarker-confirmed mild cognitive impairment due to AD compared to cognitively normal participants (p = 0.04). CONCLUSION: Long-term systolic blood pressure variability is elevated in cognitive impairment due to AD. Blood pressure variability may represent an understudied aspect of vascular dysfunction in AD with potential clinical implications.
BACKGROUND: Elevated blood pressure is linked to cognitive impairment and Alzheimer's disease (AD) biomarker abnormality. However, blood pressure levels vary over time. Less is known about the role of long-term blood pressure variability in cognitive impairment and AD pathophysiology. OBJECTIVE: Determine whether long-term blood pressure variability is elevated across the clinical and biomarker spectrum of AD. METHODS:Alzheimer's Disease Neuroimaging Initiative participants (cognitively normal, mild cognitive impairment, AD [n = 1,421]) underwent baseline exam, including blood pressure measurement at 0, 6, and 12 months. A subset (n = 318) underwent baseline lumbar puncture to determine cerebrospinal fluid amyloid-β and phosphorylated tau levels. Clinical groups and biomarker-confirmed AD groups were compared on blood pressure variability over 12 months. RESULTS: Systolic blood pressure variability was elevated in clinically diagnosed AD dementia (VIM: F2,1195 = 6.657, p = 0.001, η2 = 0.01) compared to cognitively normal participants (p = 0.001), and in mild cognitive impairment relative to cognitively normal participants (p = 0.01). Findings were maintained in biomarker-confirmed AD (VIM: F2,850 = 5.216, p = 0.006, η2 = 0.01), such that systolic blood pressure variability was elevated in biomarker-confirmed dementia due to AD relative to cognitively normal participants (p = 0.005) and in biomarker-confirmed mild cognitive impairment due to AD compared to cognitively normal participants (p = 0.04). CONCLUSION: Long-term systolic blood pressure variability is elevated in cognitive impairment due to AD. Blood pressure variability may represent an understudied aspect of vascular dysfunction in AD with potential clinical implications.
Entities:
Keywords:
Alzheimer’s disease; amyloid; blood pressure; cognitive dysfunction; tau zzm321990proteins
Authors: Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri Journal: Stroke Date: 2011-07-21 Impact factor: 7.914
Authors: Rianne A A de Heus; Marcel G M Olde Rikkert; Phillip J Tully; Brian A Lawlor; Jurgen A H R Claassen Journal: Hypertension Date: 2019-09-23 Impact factor: 10.190
Authors: Bo Qin; Anthony J Viera; Paul Muntner; Brenda L Plassman; Lloyd J Edwards; Linda S Adair; Barry M Popkin; Michelle A Mendez Journal: Hypertension Date: 2016-05-23 Impact factor: 10.190
Authors: Zoe Arvanitakis; Ana W Capuano; Melissa Lamar; Raj C Shah; Lisa L Barnes; David A Bennett; Julie A Schneider Journal: Neurology Date: 2018-07-11 Impact factor: 9.910
Authors: Isabel J Sible; Belinda Yew; Shubir Dutt; Yanrong Li; Anna E Blanken; Jung Yun Jang; Jean K Ho; Anisa J Marshall; Arunima Kapoor; Aimée Gaubert; Katherine J Bangen; Virginia E Sturm; Xingfeng Shao; Danny J Wang; Daniel A Nation Journal: Neuroimage Rep Date: 2022-01-18
Authors: Rianne A A de Heus; Christophe Tzourio; Emily Jo Lynn Lee; Melissa Opozda; Andrew D Vincent; Kaarin J Anstey; Albert Hofman; Kazuomi Kario; Simona Lattanzi; Lenore J Launer; Yuan Ma; Rajiv Mahajan; Simon P Mooijaart; Michiaki Nagai; Ruth Peters; Deborah Turnbull; Yuichiro Yano; Jurgen A H R Claassen; Phillip J Tully Journal: Hypertension Date: 2021-09-20 Impact factor: 9.897
Authors: Isabel J Sible; Belinda Yew; Jung Yun Jang; John Paul M Alitin; Yanrong Li; Aimée Gaubert; Amy Nguyen; Shubir Dutt; Anna E Blanken; Jean K Ho; Anisa J Marshall; Arunima Kapoor; Fatemah Shenasa; Kathleen E Rodgers; Virginia E Sturm; Elizabeth Head; Alessandra Martini; Daniel A Nation Journal: Sci Rep Date: 2022-10-13 Impact factor: 4.996